Viral Vector Quality: No Estimates. Only Evidence

Section 1 | Understanding Modern Viral Vector Quality

Understand the critical quality attributes that define AAV performance.

• Characterizing AAVs (eBook) — Learn how key attributes such as encapsidation, aggregation, potency, purity, and genome integrity influence AAV quality and what analytical strategies are needed to characterize them with confidence.

Section 2 | Empty, Full. And Partial Capsids Too.

Directly measure the complete capsid population with CDMS.

• White Paper: Xevo CDMS Characterization of Viruses and Viral-based Therapeutics — Discover how direct mass measurement reveals viral vector heterogeneity and provides a more complete understanding of capsid populations and product quality.
• App Note: Streamlined Characterization of Recombinant AAVs via Charge Detection Mass Spectrometry — Insights from the USP AAV8 Reference Standards— See how CDMS accurately characterizes AAV reference materials and generates robust data to support development, comparability, and QC workflows.
• App Note: Characterization with Relative Quantitation of Adeno-Associated Viruses (AAVs) using Xevo Charge Detection Mass Spectrometry (CDMS)— Directly distinguish empty, partial, full, and overfilled capsids while detecting additional impurities in a single analysis.

Section 3 | Multiple Critical Quality Attributes (CQAs) in a Single Run

Cut analysis time by measuring empty/full ratio, size, titer, and more with multi-angle light scattering.

• App Note: Quantifying Quality Attributes of AAV Gene Therapy Vectors by SEC-MALS-UV-dRI— Uncover hidden heterogeneity that can impact product performance. Simultaneously measure aggregates, capsid titer, genome titer, molecular weight, size, and empty/full ratio from a single analysis.
• App Note: Real-Time Monitoring and Control of AAV Chromatographic Enrichment by RT-MALS— Monitor AAV enrichment as it happens to improve process understanding, increase consistency, and reduce manufacturing risk.